<SEC-DOCUMENT>0001193125-26-010344.txt : 20260112
<SEC-HEADER>0001193125-26-010344.hdr.sgml : 20260112
<ACCEPTANCE-DATETIME>20260112160102
ACCESSION NUMBER:		0001193125-26-010344
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260112
DATE AS OF CHANGE:		20260112

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galecto, Inc.
		CENTRAL INDEX KEY:			0001800315
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				371957007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91812
		FILM NUMBER:		26526669

	BUSINESS ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		45-70-70-52-10

	MAIL ADDRESS:	
		STREET 1:		75 STATE STREET
		STREET 2:		SUITE 100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galecto Inc.
		DATE OF NAME CHANGE:	20200116

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Paragon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001861055
		ORGANIZATION NAME:           	
		EIN:				862707757
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		C/O FAIRMOUNT FUNDS MANAGEMENT, LLC
		STREET 2:		2001 MARKET STREET, SUITE 2500
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(267) 760-4066

	MAIL ADDRESS:	
		STREET 1:		C/O FAIRMOUNT FUNDS MANAGEMENT, LLC
		STREET 2:		2001 MARKET STREET, SUITE 2500
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001861055</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.00001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>11/10/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001800315</issuerCik>
        <issuerName>Galecto, Inc.</issuerName>
        <issuerCusip>36322Q206</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">75 State Street</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 100</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Boston</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">02109</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Paragon Therapeutics, Inc.</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>120473</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>120473</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>120473</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.5</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>
The securities exclude shares of common stock, par value $0.00001 per share ("Common Stock") issuable upon the conversion of shares of Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series C Preferred Stock") directly held by the Reporting Person. Subject to receiving approval by the Issuer's stockholders of the issuance of shares of Common Stock upon the conversion of Series C Preferred Stock in accordance with Nasdaq rules and the Beneficial Ownership Limitation set by the Reporting Person described below, each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock. Due to the conversion limitations on the Series C Preferred Stock, shares of Common Stock issuable upon the conversion of Series C Preferred Stock, if approved by the Issuer's stockholders, have been excluded from beneficial ownership set forth above. The shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock held by the Reporting Person are subject to a Beneficial Ownership Limitation of 4.99%.

Row 11 is based on 1,597,321 shares of Common Stock outstanding as of December 29, 2025 as reported in the Issuer's definitive proxy statement on Schedule DEF 14A filed with the Securities and Exchange Commission on December 31, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Galecto, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>75 State Street, Suite 100, Boston, Massachusetts, 02109</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Paragon Therapeutics, Inc.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>221 Crescent St., Building 23, Suite 105, Waltham, MA 02453</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See the response to Item 9 on the attached cover page.</amountBeneficiallyOwned>
        <classPercent>See the response to Item 11 on the attached cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See the response to Item 5 on the attached cover page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See the response to Item 6 on the attached cover page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See the response to Item 7 on the attached cover page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See the response to Item 8 on the attached cover page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Paragon Therapeutics, Inc.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Keri Lantz</signature>
        <title>Keri Lantz, Chief Financial Officer</title>
        <date>01/12/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
